Neoadjuvant L19IL2/L19TNF- Pivotal Study
A phase 3 trial of L19IL2 + L19TNF in melanoma, run by Philogen S.p.A., active and no longer recruiting.
Overview
Neoadjuvant L19IL2/L19TNF- Pivotal Study is a phase 3 interventional study registered as NCT02938299 by Philogen S.p.A., with 214 participants enrolled, started 2016-07-01 and due to reach its primary completion in 2024-10. Interventions recorded: L19IL2 + L19TNF and Surgery.
Setting
A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients
Phase
Phase 3
Sponsor
Philogen S.p.A.
Registry
Enrolled
214
Similar pages
not linked directly; found by shared links- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Philogen S.p.A., Melanoma and the tag pipeline.
- TrialA Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Shares Philogen S.p.A. and the tag pipeline.
- TrialL19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Shares Philogen S.p.A. and the tag pipeline.
- TrialL19IL2/TNF in Patients With Basal Cell Carcinoma
Shares Philogen S.p.A. and the tag pipeline.
- TrialSafety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Shares Philogen S.p.A. and the tag pipeline.
- TrialStudy of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Shares Philogen S.p.A., Melanoma.
- TrialPhase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Shares Melanoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.